ONCO

Onconetix, Inc.

$3.47

-3.07%
SectorHealthcareIndustryBiotechnologyCountryUnited States

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.

Source: Yahoo Finance
AI summary

Price & performance

1M-44.0%
3M-61.4%
YTD-99.6%
1Y-99.7%
52-week range—
Beta0.90
Full chart and returns against a benchmark

Q-Score

12/ 100

Quality against peers; 50 is the peer median.

Growth13
Risk12
Performance5
Valuation35
Profitability40
Leverage35
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$815.4K-67.7%
Net income-$14M
Net margin—
Historical fundamentals

Red flags in filings

3active red flags
Going-concern doubtMar 13, 2026
Material weakness in controlsMar 13, 2026
Auditor changeFeb 18, 2025
Filings, findings and the timeline

Revenue exposure

Switzerland98%
United Kingdom2%
Largest customer100%
Regions, segments, customers and suppliers

Valuation

ONCOIndustryP/E—89.69P/S3.1611.88EV/EBITDA—67.10P/B0.156.22PEG—4.02
Dividend yield0.00%
Every valuation metric